drugset / Trial / NCT05439824
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006）in healthy participants aged 18 or more.
Timeline
- Start
- 2022-06-28
- Primary completion
- 2023-01-12
- Completion
- 2023-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SYS6006 | Messenger RNA (mRNA) | 20 ug | Intramuscular |
| Subject | SYS6006 | Messenger RNA (mRNA) | 30 ug | Intramuscular |